984-P: Reduced Rate of Hospitalizations for Acute Diabetes Events Before and After FreeStyle Libre System Initiation in People with Type 2 Diabetes on Insulin-Secretagogue Oral Drug Therapy in France

Introduction: People with T2D treated with oral insulin-secretagogues are at risk for acute diabetes events (ADEs), including DKA and hypoglycemia. This study investigates the change in hospitalization rates for ADEs following initiation of FreeStyle Libre® system (FSL), in people with T2D in France, treated with oral insulin-secretagogue drugs without insulin. Methods: Retrospective study of the French national SNDS claims database identified people with T2D treated with insulin-secretagogues without insulin and a FSL initiation date between 01/Aug/2017 to 31/Dec/2018. Data for the 12 months before and after FSL initiation were included. Hospitalizations were identified using ICD-10 codes for: DKA; hyperglycemia; hypoglycemic events; comas. Results: 4,962 people with T2D on oral insulin-secretagogue drugs initiated FSL during the selection period. Of these, 8.7% had at least one hospitalization for any ADE in the year before FSL initiation, compared to 2.4% in the year after initiation (Fig 1), a reduction of 72%. The reduction in ADEs was driven by -81% fewer admissions for DKA or hyperglycemia. Conclusions: This study suggests that use of the FSL system is associated with reduced hospital admissions for ADEs in people with T2D in France, treated with oral insulin-secretagogue drugs without insulin. Disclosure B. Guerci: Advisory Panel; Abbott Diagnostics, Eli Lilly and Company, Novo Nordisk A/S, Sanofi, AstraZeneca, Bayer Inc., Medtronic, Insulet Corporation, Dexcom, Inc., Boehringer-Ingelheim. F. Levrat-Guillen: Employee; Abbott. B. Detournay: Advisory Panel; AstraZeneca. Consultant; Abbott, AstraZeneca, Novo Nordisk, Sanofi, CEMKA, CERBA expert. E. Vicaut: Consultant; Abbott, Boston Scientific Corporation, COLOPLAST. G. DePouvourville: Advisory Panel; Abbott, Alexion Pharmaceuticals, Inc., AstraZeneca, Astellas Pharma Inc., Bayer Inc., Boehringer-Ingelheim, Bristol-Myers Squibb Company, Biogen. Research Support; GlaxoSmithKline plc. Advisory Panel; IQVIA Inc., Lundbeck, Janssen Pharmaceuticals, Inc., Moderna, Inc., Novartis Pharmaceuticals Corporation, Takeda Pharmaceutical Company Limited, Viatris Inc., Edwards Life Sciences, UCB, Alexion Pharmaceuticals, Inc., DBV-Technology, EFPIA. C. Emery: None. J. Riveline: Board Member; Abbott, Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Medtronic, Dexcom, Inc., Insulet Corporation, Air Liquide, AstraZeneca. Funding Abbott